Day One Biopharmaceuticals, Inc. has entered into an agreement to acquire Mersana Therapeutics, Inc. on November 12, 2025, offering $25.00 per share plus contingent value rights for future milestone payments. The merger is expected to close by January 2026, pending regulatory approvals and other conditions.